Literature DB >> 18466393

Investigation of the immunomodulatory effects of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection.

Li Zhang1, Ping Su, Anders Henriksson, Jani O'Rourke, Hazel Mitchell.   

Abstract

BACKGROUND: Lactobacillus and Bifidobacterium species have shown beneficial effects in the treatment of Helicobacter pylori infection; however, the mechanisms behind such effects are not fully understood. In this study, we have investigated the immunomodulatory effects of probiotics in a mouse model of H. pylori infection.
MATERIALS AND METHODS: H. pylori-infected C57BL/6 mice were treated with L. casei L26, B. lactis B94, or no probiotics for 5 weeks, respectively. Mice not infected with H. pylori were included as normal controls. Gastric histology, protein levels of interleukin (IL)-1beta, IL-10, IL-12/23p40, and H. pylori colonization density in the gastric tissues, as well as H. pylori-specific antibodies were examined.
RESULTS: In mice receiving L. casei L26 and B. lactis B94, gastric neutrophil infiltration and IL-1beta were significantly decreased and IL-10 was significantly increased as compared with mice receiving no probiotics. In mice receiving B. lactis B94, IL-12/23p40 was significantly increased and H. pylori IgG was significantly reduced as compared with mice receiving no probiotics. No significant difference of H. pylori colonization was observed among the three groups of mice.
CONCLUSION: The reduced level of IL-1beta and neutrophil infiltration observed in mice infected with H. pylori following treatment with L. casei L26 and B. lactis B94 resulted from a modulation of immune response rather than a decrease of H. pylori colonization. Furthermore, B. lactis B94 has the intrinsic ability to promote a Th1 immune response through an increase in IL-12/IL-23.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466393     DOI: 10.1111/j.1523-5378.2008.00595.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  8 in total

1.  Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori.

Authors:  Luc De Vuyst; Pascal Vincent; Eleftherios Makras; Frédéric Leroy; Bruno Pot
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03       Impact factor: 4.609

2.  Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection.

Authors:  Jin-Eung Kim; Min-Soo Kim; Yeo-Sang Yoon; Myung-Jun Chung; Do-Young Yum
Journal:  J Microbiol       Date:  2014-10-03       Impact factor: 3.422

3.  Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial.

Authors:  Chien-Ying Lee; Hung-Che Shih; Min-Chien Yu; Ming-Yung Lee; Ya-Lan Chang; Ya-Yun Lai; Yi-Ching Lee; Yu-Hsiang Kuan; Chun-Che Lin
Journal:  Chin J Integr Med       Date:  2016-10-19       Impact factor: 1.978

4.  Effect and Mechanism of Bifidobacterium animalis B94 in the Prevention and Treatment of Liver Injury in Rats.

Authors:  Tianfang Zhang; Jie Wang; Zhao Yao; Lingmei Ni; Yifan Zhao; Shuang Wei; Zuobing Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-06-29       Impact factor: 6.073

5.  Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease.

Authors:  Li Zhang; Si Ming Man; Andrew S Day; Steven T Leach; Daniel A Lemberg; Shoma Dutt; Michael Stormon; Anthony Otley; Edward V O'Loughlin; Annabel Magoffin; Patrick H Y Ng; Hazel Mitchell
Journal:  J Clin Microbiol       Date:  2008-12-03       Impact factor: 5.948

6.  Gastric cancer mortality trends in Spain, 1976-2005, differences by autonomous region and sex.

Authors:  Esther García-Esquinas; Beatriz Pérez-Gómez; Marina Pollán; Elena Boldo; Pablo Fernández-Navarro; Virginia Lope; Enrique Vidal; Gonzalo López-Abente; Nuria Aragonés
Journal:  BMC Cancer       Date:  2009-09-28       Impact factor: 4.430

Review 7.  Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.

Authors:  Yiming Wang; Rena Ma; Fang Liu; Seul A Lee; Li Zhang
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

8.  The Exopolysaccharide of Lactobacillus fermentum UCO-979C Is Partially Involved in Its Immunomodulatory Effect and Its Ability to Improve the Resistance against Helicobacter pylori Infection.

Authors:  Valeria Garcia-Castillo; Guillermo Marcial; Leonardo Albarracín; Mikado Tomokiyo; Patricia Clua; Hideki Takahashi; Haruki Kitazawa; Apolinaria Garcia-Cancino; Julio Villena
Journal:  Microorganisms       Date:  2020-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.